4月10日 - ** 药物开发商Keros Therapeutics KROS.O股价盘前上涨17.4%至12.09美元
** KROS称， (link)，其董事会已经批准了一项股东权利计划，也被称为 "毒丸"，以应对一些投资者快速积累公司股票的情况。
** 公司还启动了一项评估战略选择的程序，包括可能的出售
** 截至上次收盘，公司股价累计下跌 34.7
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.